Tectonic Therapeutic

TECX Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-26

Catalyst timeline

AZD5462 AstraZeneca Ph2b readout2H 2026AZD5462 AstraZeneca Ph2b readout, 2H 2026, notable
TX2100 toplinelate 3Q 2026TX2100 topline, late 3Q 2026, major
TX45 toplineearly 1Q 2027TX45 topline, early 1Q 2027, thesis-defining
TX45 readout1Q 2027TX45 readout, 1Q 2027, material
TX2100 Ph2 startplanned early 2027TX2100 Ph2 start, planned early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

TX45

Protein Target: RXFP1

Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction Phase 2 subcutaneous
Pulmonary Hypertension Associated with Interstitial Lung Disease Phase 2 subcutaneous

TX2100

Protein Target: APJ, APLNR

Hereditary Hemorrhagic Telangiectasia Phase 1 subcutaneous

Technology platforms

GEODe

GPCRs Engineered for Optimal Discovery — proprietary yeast display platform for discovering biologic drugs (antibodies, Fab, VHH) targeted to GPCRs; enables stabilization of pharmacologically relevant GPCR conformations for naïve antibody selection; focus areas include cardiovascular, fibrotic, and rare diseases

Biotech Distilled coverage (3)

2026-08-07 UPDATE: Tectonic Therapeutic (TECX) - The IDMC Looked at 80% of the Data and Didn’t Blink 🔒 Paid
2026-06-10 UPDATE: Tectonic Therapeutic (TECX) - The Clock is Set
2026-06-09 Tectonic Therapeutic (TECX) — Scientific Deep Dive for TX45 (Relaxin/RXFP1) and TX2100 (APJ Antagonist)

Articles open on Substack. Some deep dives are subscriber-only.